Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 10
2005 16
2006 30
2007 30
2008 21
2009 36
2010 38
2011 45
2012 50
2013 62
2014 57
2015 56
2016 58
2017 51
2018 72
2019 65
2020 72
2021 61
2022 36
Text availability
Article attribute
Article type
Publication date

Search Results

748 results
Results by year
Filters applied: . Clear all
Page 1
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F. Minozzi S, et al. Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783. Expert Opin Drug Saf. 2016. PMID: 27924643 Free article. Review.
Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection
Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs …
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. Singh S, et al. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13. Clin Gastroenterol Hepatol. 2020. PMID: 31945470 Free PMC article. Review.
In patients with prior exposure to TNF antagonists, ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99; 95% CI, 1.13-31.76 and tofacitinib vs vedoli …
In patients with prior exposure to TNF antagonists, ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for inductio …
Adalimumab: a review of side effects.
Scheinfeld N. Scheinfeld N. Expert Opin Drug Saf. 2005 Jul;4(4):637-41. doi: 10.1517/14740338.4.4.637. Expert Opin Drug Saf. 2005. PMID: 16011443 Review.
It does not require laboratory monitoring. The most common side effects of adalimumab are injection site reactions. Adalimumab increases the risk of rare serious infections. There is a two-fold risk of serious infections with the use of …
It does not require laboratory monitoring. The most common side effects of adalimumab are injection site reactions. Adalimumab
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
Bechara FG, Podda M, Prens EP, Horváth B, Giamarellos-Bourboulis EJ, Alavi A, Szepietowski JC, Kirby J, Geng Z, Jean C, Jemec GBE, Zouboulis CC. Bechara FG, et al. JAMA Surg. 2021 Nov 1;156(11):1001-1009. doi: 10.1001/jamasurg.2021.3655. JAMA Surg. 2021. PMID: 34406349 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial was a phase 4, randomized, double-blind, placebo-controlled study of adalimumab in conjunction with surgery. ...Treatment-emergent ad …
DESIGN, SETTING, AND PARTICIPANTS: The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial …
Hidradenitis suppurativa: Current and emerging treatments.
Goldburg SR, Strober BE, Payette MJ. Goldburg SR, et al. J Am Acad Dermatol. 2020 May;82(5):1061-1082. doi: 10.1016/j.jaad.2019.08.089. Epub 2019 Oct 9. J Am Acad Dermatol. 2020. PMID: 31604100 Review.
Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Penso L, et al. JAMA Dermatol. 2021 Sep 1;157(9):1056-1065. doi: 10.1001/jamadermatol.2021.2599. JAMA Dermatol. 2021. PMID: 34287624 Free PMC article.
After adjusting for time-dependent covariables, risk of serious infections was higher for new users of adalimumab (wHR, 1.22; 95% CI, 1.07-1.38) or infliximab (wHR, 1.79; 95% CI 1.49-2.16) vs etanercept, whereas ustekinumab was associated with a lower risk
After adjusting for time-dependent covariables, risk of serious infections was higher for new users of adalimumab (wHR, …
Biologic Agents and Tuberculosis.
Dobler CC. Dobler CC. Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0026-2016. Microbiol Spectr. 2016. PMID: 28084208 Free article. Review.
Treatment with biologic agents, in particular tumor necrosis factor alpha (TNF-alpha) inhibitors, is associated with an increased risk of tuberculosis (TB), and screening and treatment for latent TB infection (LTBI) in patients undergoing such treatment is therefore …
Treatment with biologic agents, in particular tumor necrosis factor alpha (TNF-alpha) inhibitors, is associated with an increased risk
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP. Nguyen QD, et al. Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Lancet. 2016. PMID: 27542302 Free article. Clinical Trial.
The 40th percentile for time to treatment failure was 4.8 months in the placebo group and 10.2 months in the adalimumab group. No patients in either group had opportunistic infections (excluding oral candidiasis and tuberculosis). ...INTERPRETATION: Adalimumab
The 40th percentile for time to treatment failure was 4.8 months in the placebo group and 10.2 months in the adalimumab group. No pat …
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC. Li X, et al. Ann Rheum Dis. 2020 Feb;79(2):285-291. doi: 10.1136/annrheumdis-2019-216102. Epub 2019 Oct 31. Ann Rheum Dis. 2020. PMID: 31672774 Free PMC article.
By contrast, IL-23/23 were associated with a lower risk of infections than TNF (HR=0.59, 95% CI 0.39 to 0.90). CONCLUSIONS: Relative to TNF and IL-17, IL-12/23 inhibitors were associated with a reduced risk of serious infection in biologic-naive patien …
By contrast, IL-23/23 were associated with a lower risk of infections than TNF (HR=0.59, 95% CI 0.39 to 0.90). CONCLUSIONS: Re …
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K. Warren RB, et al. N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. N Engl J Med. 2021. PMID: 33891379 Clinical Trial.
At week 16, a total of 275 of 319 patients (86.2%) who received bimekizumab (both dose groups combined) and 75 of 159 (47.2%) who received adalimumab had a PASI 90 response (adjusted risk difference, 39.3 percentage points; 95% confidence interval [CI], 30.9 to 47.7 …
At week 16, a total of 275 of 319 patients (86.2%) who received bimekizumab (both dose groups combined) and 75 of 159 (47.2%) who received …
748 results